Samsung Bioepis Brings in Lawyers to Sue AbbVie in Biosimilars Push

Published: Apr 04, 2016

Samsung Bioepis Co Ltd, which aims to become a force in the fledgling biosimilar drugs industry, has filed a lawsuit against the originator of the world's best-selling drug, to stop it blocking the launch of its own version.

The unit of South Korea's Samsung Group [SAGR.UL], along with partner and minority shareholder Biogen, filed suit in Britain on March 24 against AbbVie Inc, maker of rheumatoid arthritis drug Humira, which generated sales of $14 billion last year.

It is the company's first suit against a drug originator.

Back to news